+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effects of Rezpegaldesleukin in people aged 12 years and older who have moderate to severe atopic dermatitis. This Phase 3, randomized, double-blind study compares Rezpegaldesleukin to a placebo to assess its impact on skin symptoms and severity over approximately 15 months. The goal is to better understand how this treatment influences the condition in participants who have not responded well to topical therapies. Participants will receive Rezpegaldesleukin or a placebo by subcutaneous injection during an induction period every 2 weeks. This is followed by a maintenance period with Rezpegaldesleukin given either every 4 or 12 weeks or placebo every 4 weeks. There is also an open-label escape phase where dosing frequency of Rezpegaldesleukin is adjusted by the investigator. Treatments are administered under blinded conditions during the induction and maintenance phases. During the study, participants will have their skin condition evaluated through assessments like the Investigators Global Assessment IGA and Eczema Area and Severity Index EASI. Other measurements include itch and skin pain scales, sleep quality, and questionnaires related to asthma and sinus symptoms. Safety is monitored by tracking adverse events through about week 56 of participation. The overall study duration for each participant is about 15 months.

Age: 12Years +All GendersPhase 3
13 locations
E

Actively Recruiting

Researchers are studying the effects of Deucravacitinib BMS-986165 in adolescents aged 12 to 17 years with moderate to severe plaque psoriasis. The study aims to assess the drugs effectiveness, safety, and how it behaves in the body. This phase 3 trial is designed as a randomized, double-blind, placebo-controlled investigation to provide clear evidence of the drugs impact in this younger population. Participants are randomly assigned to receive either Deucravacitinib or a placebo following specified dosing schedules. The study involves a parallel group design where the treatment is given on specified days. The trial will monitor participants closely over time to evaluate treatment responses and any side effects, especially focusing on improvements in psoriasis severity and skin condition. During the study, participants will have regular assessments including measurement of psoriasis severity by Psoriasis Area and Severity Index PASI and Physicians Global Assessment sPGA, body surface area affected, itch severity, and quality of life. Safety monitoring includes checking for adverse events, laboratory tests, physical exams, vital signs, and vaccine antibody levels. The study also tracks growth and sexual maturation over up to five years, providing long-term data on drug safety and participant health.

Age: 12Years - 17YearsAll GendersPhase 3
133 locations